CanadaBis Capital Inc. (TSXV:CANB.P) has launched its campaign on the Investing News Network’s cannabis channel.

CanadaBis Capital is a Canadian cannabis company developing a diverse business model built upon four main pillars: cultivation, research and product development, retail and hemp. The company aims to create a vertically-integrated model before it begins expansion throughout Canada. In order to drive its cultivation business, CanadaBis has acquired Stigma Grow, a cannabis cultivation company in development of a 66,000-square foot craft cannabis cultivation facility in Red Deer, Alberta.


Once construction of the first building is complete, Stigma Grow plans to add another 66,000-square foot facility directly adjacent to the first. This doubling of the company’s cultivation space is expected to increase Stigma Grow’s total production to 32,000 kilograms annually. Stigma Grow has also secured an additional 800,000 square feet of cultivation and processing space to be used in future cultivation operations. The company has developed 42 proprietary strains that have proven to be mold, mildew and pest resistant after three years of research and development.

CanadaBis Capital’s company highlights include the following:

  • Canadian cannabis market to generate up to $7.17 billion in sales in 2019.
  • Alberta’s recreational cannabis market to reach $1 billion per year.
  • Stigma Grow has a 66,000-square-foot craft cannabis cultivation facility in Red Deer, Alberta which is expected to produce up to 16,000 kilograms of cannabis annually with a gross margin of $84 million.
  • Developed 42 unique, proprietary strains that are mold, mildew and pest resistant.
  • Working to acquire a wholly-owned retail location in Red Deer’s “Gasoline Alley”.
  • Anticipated revenue generation of $9 million annually per retail store once Health Canada legalizes value-added products.
  • In discussions to acquire a cannabis R&D facility in Alberta.

Click here to see the educational profile for CanadaBis Capital Inc. (TSXV:CANB.P) and to request an investor presentation.

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to announce that it has issued a total of 7,400,000 options pursuant to its incentive stock option plan (“Plan”) to management, employees and consultants. Each option entitles the holder to subscribe for one common share of the Company for $0.265 for a period of 5 years, subject to the terms of the Plan

The Company has also agreed to engage Aktiencheck.de AG, for €50,000 for a European marketing and news dissemination program. The length of such program depends upon the Company’s future news flow.

Keep reading... Show less
  • Company has received UK Continuing Professional Development (“CPD”) accreditation for its global education platform, Khiron Academy
  • UK medical professionals may now earn CPD credits through Khiron’s medical cannabis education program
  • The Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK, to increase patient access via medical cannabis education
  • As a leading international medical cannabis educator, nearly 1,000 medical professionals in Latin America and the United Kingdom have registered for, or completed, Khiron Academy training

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe is pleased to announce it has received UK Continuing Professional Development (“CPD”) accreditation for Khiron Academy, the Company’s global medical cannabis education platform.

Additionally, following its accreditation, the Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK and fellow founding member of Project Twenty21, to increase patient access through medical cannabis education initially. Khiron Academy will be made available to prescribers in the UK that have registered with Cellen’s MedCanHub, an emerging education portal. Cellen is market leader, widely recognized for also launching the UK’s first digital pain clinic, Leva.

Keep reading... Show less

TRACE’s plant-based and alkaline wellness products to expand into key markets of Japan, China and the Philippines

Emerging leader in innovative health and wellness beverages and consumer products, BevCanna Enterprises Inc . ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today its anticipated expansion into the Asia Pacific region, through its wholly-owned subsidiary Naturo Group. After completing a comprehensive market, distribution and partner assessment, the Company intends to initially launch its portfolio of TRACE health and wellness products in the key markets of Japan, China, and the Philippines, through multi-channel distribution outlets including e-commerce, retail, and wholesale.

Keep reading... Show less

Trulieve acquires dispensary permits from Solevo Wellness West Virginia LLC for $650,000

Trulieve Cannabis Corp . (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States and the largest cannabis company in Florida announced today that it acquired Solevo Wellness West Virginia LLC (“Solevo”) and its three West Virginia dispensary permits for $650,000 . Solevo was awarded two permits in Morgantown and one in Parkersburg in January 2021 as part of the West Virginia application process.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) a wellness company that develops and sells sustainable, plant-based products, is pleased to announce that it’s Jusu Home and Body line is now available for purchase on Faire Wholesale Marketplace (“Faire” or “www.faire.com”), an online wholesale marketplace valued at US $2.5 billion. Jusu Home and Body products are currently featured in their “New Arrivals” section.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/80230_8c77c54544bf884c_001.jpg

Keep reading... Show less